Figure 14.1 Outline of dopamine replacement therapy. Reprinted with permission, Cleveland Clinic Center for Medical Art and Photography, 2014. All Rights Reserved. Unfamiliarity with the delicate nuances of DRT can…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 13 Management of disease-related behavioral disturbances in Parkinson’s disease Joseph H. Friedman Introduction Although categorized as a movement disorder, Parkinson’s disease (PD) is a neurobehavioral…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 12 A neurobehavioralist approach to the management of cognitive impairment in Parkinson’s disease Po-Heng Tsai Introduction Parkinson’s disease (PD) is traditionally characterized by its motor…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 11 Management of cognitive impairment in Parkinson’s disease Dawn M. Schiehser, Eva Pirogovsky-Turk and Irene Litvan Background on cognitive impairment in Parkinson’s disease Cognitive impairment…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 10 Management of autonomic dysfunction in Parkinson’s disease Shen-Yang Lim and Ai Huey Tan Introduction Autonomic dysfunction can occur many years before a diagnosis of…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 9 Experimental pharmacological agents in the management of Parkinson’s disease Krishe Menezes, Lawrence W. Elmer and Robert A. Hauser Introduction On the contrary, there appears…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 8 Catechol-O-methyltransferase inhibitors in the management of Parkinson’s disease Ilana Schlesinger and Amos D. Korczyn The introduction of 3,4-dihydroxyphenylalanine (DOPA) to the treatment of Parkinson’s…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 5 Oral dopamine agonists in the management of Parkinson’s disease Javier Pagonabarraga, Juan Marín-Lahoz and Jaime Kulisevsky Introduction and history In 1960 and 1967, Hornykiewicz…
html xmlns=”http://www.w3.org/1999/xhtml” xmlns:mml=”http://www.w3.org/1998/Math/MathML” xmlns:epub=”http://www.idpf.org/2007/ops”> Chapter 4 Monoamine oxidase inhibitors in the management of Parkinson’s disease Sven-Eric Pålhagen Introduction Monoamine oxidase B (MAO-B) inhibitors have again become relevant as a good…
Figure 2.1 Prescription of anticholinergic treatment used by Professor Charcot, dated 1887 from the College of Physicians of Philadelphia Library. The cholinergic system and Parkinson’s disease Some authors have postulated…
